A Phase II Randomised, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Four Orally Administrated Doses of BI 409306 During a 12-week Treatment Period in Patients With Schizophrenia on Stable Antipsychotic Treatment
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009021/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The objective of the study is to investigate the efficacy, safety and tolerability of four
different doses of BI 409306 once daily compared to placebo given for 12 weeks in patients
with schizophrenia on stable antipsychotic treatment.
提供机构：
Vivli
创建时间：
2023-06-15
